Canaccord raised the firm’s price target on Boston Scientific (BSX) to $98 from $88 and keeps a Buy rating on the shares. The firm updated its model to include the acquisition of Silk Road Medical. The deal closed on 09/17/24 at an EV of $1.18B. Canaccord said management EPS guidance is immaterial to 2025 and accretive to 2026, thus they maintaied their adjusted EPS estimate of $2.41 for 2024 and raised their 2025 estimate to $2.68.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Is BSX a Buy, Before Earnings?
- Boston Scientific launches next-gen cardiac mapping for FARAPULSE
- Netflix reports Q3 beat, CVS CEO Lynch steps down: Morning Buzz
- Boston Scientific downgraded, Datadog upgraded: Wall Street’s top analyst calls
- Boston Scientific price target raised to $100 from $85 at Stifel